Published in Rev Urol on January 01, 2000
The changing natural history of renal cell carcinoma. J Urol (2001) 4.72
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol (1999) 1.63
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med (2001) 1.29
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15
Gene and immune-based therapies for genitourinary malignancies: current status and future prospects. Isr Med Assoc J (2000) 1.07
Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology (2001) 1.05
Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res (1997) 1.04
Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin. J Urol (1999) 1.00
Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther (1995) 0.95
Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int (2004) 0.94
CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol (2000) 0.93
Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol (2001) 0.89
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest (1996) 0.89
Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother (2001) 0.87
Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. J Urol (1997) 0.87
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther (2001) 0.85
In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer (1996) 0.85
Prognostic factors and molecular markers for renal cell carcinoma. Expert Rev Anticancer Ther (2001) 0.84
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol (2001) 0.84
Adenocarcinoma of the urachus and bladder expresses a unique colonic epithelial epitope: an immunohistochemical study. J Urol (1997) 0.83
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol (2001) 0.82
Behçet's syndrome with left ventricular aneurysm and ruptured renal artery pseudoaneurysm. Urology (1999) 0.82
Management of penile toilet seat injury--report of two cases. Can J Urol (2001) 0.81
Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4. J Immunother (1991) (1992) 0.80
Endovascular stent graft for management of ureteroarterial fistula after orthotopic bladder substitution. Tech Urol (1999) 0.80
Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications. Hum Gene Ther (1992) 0.79
Immunotherapy of prostate cancer. Curr Urol Rep (2001) 0.79
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. Evid Based Complement Alternat Med (2013) 0.78
Laparoscopic radical nephrectomy. Semin Urol Oncol (2001) 0.77
Interferon alpha for the treatment of superficial bladder cancer. Adv Exp Med Biol (1999) 0.77
The utility of PSA doubling time to monitor prostate cancer recurrence. Mayo Clin Proc (2001) 0.77
Dendritic cell-based immunotherapy of renal cell carcinoma. Curr Urol Rep (2001) 0.76
Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. J Urol (2001) 0.76
Rethinking staging and treatment for renal cell cancer. Rev Urol (2001) 0.75
Biomarkers for early detection and optimized treatment for transitional cell carcinoma. Rev Urol (2001) 0.75
Re: leech therapy for massive scrotal hematoma following percutaneous transluminal angioplasty. J Urol (1998) 0.75
Molecular markers for renal cell carcinoma. Rev Urol (2000) 0.75
Determining the optimal treatment for advanced bladder cancer. Rev Urol (2001) 0.75
Immune and genetic therapies for advanced renal cell carcinoma. Rev Urol (2000) 0.75
Interferon and kidney cancer: a promise unfulfilled? Cancer J Sci Am (1998) 0.75
Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol (2001) 0.75
Molecular-based therapies for renal cell carcinoma. Curr Urol Rep (2001) 0.75
Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br J Urol (1997) 0.75
Towards kidney cancer crystal ball. Better prognostication of patients with renal cell carcinoma. J Urol (2001) 0.75
Combined cytoreductive laser therapy and immunotherapy for palliation of metastatic renal cell carcinoma to the head and neck. Lasers Med Sci (2007) 0.75
Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions. World J Urol (2000) 0.75
Gene therapy for prostate cancer. New perspectives on an old problem. Urol Clin North Am (1999) 0.75
Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer. Curr Urol Rep (2001) 0.75
Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association. Rev Urol (2001) 0.75